FATE - FATE THERAPEUTICS INC
IEX Last Trade
1.605
-0.025 -1.558%
Share volume: 22,812
Last Updated: Fri 27 Dec 2024 05:29:46 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$1.63
-0.03
-1.53%
Fundamental analysis
10%
Profitability
0%
Dept financing
7%
Liquidity
75%
Performance
4%
Performance
5 Days
0 0%
1 Month
-38.06%
3 Months
-52.57%
6 Months
-49.08%
1 Year
-55.38%
2 Year
-84.92%
Key data
Stock price
$1.60
DAY RANGE
$1.58 - $1.71
52 WEEK RANGE
$1.68 - $8.83
52 WEEK CHANGE
-$57.87
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: J. Scott Wolchko
Region: US
Website: fatetherapeutics.com
Employees: 550
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: fatetherapeutics.com
Employees: 550
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Fate Therapeutics, Inc. develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cells product candidates.
Recent news